CD274 and non-small cell lung carcinoma: Clinical trials of platinum-based drugs in combination with PD-1/PD-L1 drugs are ongoing for the treatment of certain tumors, particularly non-small-cell lung cancer (NSCLC), a devastating disease with a 5-year survival rate of less than 2% 1 year after diagnosis [117].